(Sr.)Manager of Investor Relations
百济神州(北京)生物科技有限公司
- 公司规模:5000-10000人
- 公司性质:外资(欧美)
- 公司行业:制药/生物工程
职位信息
- 发布日期:2020-12-07
- 工作地点:北京
- 招聘人数:若干人
- 工作经验:无需经验
- 学历要求:招若干人
- 语言要求:不限
- 职位类别:其他
职位描述
The Manager/Senior Manager of Investor Relations will be part of the IR team which works to ensure the company is appropriately and strategically positioned with analysts, investors, and all stakeholders. The person who fills this role will be an integral part of the IR team based in China as we operate through two major stock exchanges in Asia: HKEx and Shanghai Stock Exchange – STAR Market. The candidate will participate in designing and executing all of BeiGene’s IR activities including: in-person IR events such as at medical meetings and corporate events, in-person road shows, conference calls, dissemination of data on the company and its clinical studies, and responding to events and news that impact the firm and its position and reputation. The position requires excellent communication, interpersonal and technology skills and the ability to carefully manage relationships both within the company as well as outside to create the best interface possible between the firm and its stakeholders.
Manager/Senior Manager of Investor Relations Responsibilities
The main specific responsibilities are to:
?Prepare background analysis on clinical and financial data to support the development of response to investor questions around BeiGene’s clinical data or earnings releases
?Perform analysis on sell-side analysts’ models as compared to internal projection and track estimates, ratings, reports and other relevant data
?Work with internal teams to stay informed of the status of pipeline assets and clinical programs; help craft messages describing lead candidates based on preclinical and clinical data
?Maintain existing IR presentation materials and develop new materials as needed
?Produce reports on IR activities on the Asia markets such as trading updates and investor topics debriefs
?Maintain the IR team’s investor CRM system and other databases
?Coordinate with Legal Department in Asia for company disclosure and filings to two stock exchanges
?Help prepare the company’s press releases and financial filings such as the Annual Report, 10-k and 10-q for Hong Kong and Mainland listings
职位要求:
The Manager/Senior Manager of IR should be a corporate professional who also has entrepreneurial skills and is able to keep high levels of professionalism and integrity when dealing with Asian investors and stake holders as the company proceeds through both positive and negative developments. Success in this role requires collaboration, communication, responsiveness, a can-do attitude and vision.
Qualifications desired for the Manager/Senior Manager of Investor Relations are:
?3 - 5 years of experience in investor relations, or experience on the buy or sell-side
?Advanced degree in science, strong scientific training in biotechnology and or oncology and technical skills. Experience in finance is a plus
?A Ph.D. degree is desirable
?Excellent skills in clinical data interpretation and analysis, financial modeling including techniques and valuation methods used by analysts and investors
?Familiarity with HKEx and Shanghai Stock Exchange filings and regulations
?Familiarity with Asia-based investors especially Mainland institutional investors is a plus
?Excellent written, verbal and in-person communication skills, such as an ability to draft engaging and concise messages for investor presentations
?Fluent in English and Chinese
?Must be able to perform in a high-pressure environment, and be able to meet tight deadlines
Manager/Senior Manager of Investor Relations Responsibilities
The main specific responsibilities are to:
?Prepare background analysis on clinical and financial data to support the development of response to investor questions around BeiGene’s clinical data or earnings releases
?Perform analysis on sell-side analysts’ models as compared to internal projection and track estimates, ratings, reports and other relevant data
?Work with internal teams to stay informed of the status of pipeline assets and clinical programs; help craft messages describing lead candidates based on preclinical and clinical data
?Maintain existing IR presentation materials and develop new materials as needed
?Produce reports on IR activities on the Asia markets such as trading updates and investor topics debriefs
?Maintain the IR team’s investor CRM system and other databases
?Coordinate with Legal Department in Asia for company disclosure and filings to two stock exchanges
?Help prepare the company’s press releases and financial filings such as the Annual Report, 10-k and 10-q for Hong Kong and Mainland listings
职位要求:
The Manager/Senior Manager of IR should be a corporate professional who also has entrepreneurial skills and is able to keep high levels of professionalism and integrity when dealing with Asian investors and stake holders as the company proceeds through both positive and negative developments. Success in this role requires collaboration, communication, responsiveness, a can-do attitude and vision.
Qualifications desired for the Manager/Senior Manager of Investor Relations are:
?3 - 5 years of experience in investor relations, or experience on the buy or sell-side
?Advanced degree in science, strong scientific training in biotechnology and or oncology and technical skills. Experience in finance is a plus
?A Ph.D. degree is desirable
?Excellent skills in clinical data interpretation and analysis, financial modeling including techniques and valuation methods used by analysts and investors
?Familiarity with HKEx and Shanghai Stock Exchange filings and regulations
?Familiarity with Asia-based investors especially Mainland institutional investors is a plus
?Excellent written, verbal and in-person communication skills, such as an ability to draft engaging and concise messages for investor presentations
?Fluent in English and Chinese
?Must be able to perform in a high-pressure environment, and be able to meet tight deadlines
职能类别:其他
公司介绍
百济神州是一家立足于科学的全球性生物科技公司,专注于开发创新、可负担的药物,旨在为全球患者改善治疗效果,提高药物可及性。目前公司广泛的药物组合包括40多款临床候选药物。公司通过加强自主研发能力和合作,加速推进多元、创新的药物管线开发。我们致力于在2030年前为全球20多亿人全面改善药物可及性。百济神州在全球五大洲打造了一支超过8,000人的团队。
联系方式
- Email:shan.liu@beigene.com
- 公司地址:昌平区生命科学园 (邮编:102206)